Quick Overview: FDA provides information on 180-Day and Competitive Generic Therapy exclusivities, which apply to generic drugs. Nisha Shah from the Office of Regulatory Policy discusses New Chemical Entity (NCE) and Truong Quach from the Office of Generic Drugs provides an overview of the types of exclusivities that are listed in the
Orange Book Exclusivity Part Iii - Detailed Overview & Context
FDA provides information on 180-Day and Competitive Generic Therapy exclusivities, which apply to generic drugs. Nisha Shah from the Office of Regulatory Policy discusses New Chemical Entity (NCE) and Truong Quach from the Office of Generic Drugs provides an overview of the types of exclusivities that are listed in the FDA provides information on pediatric, Generating Antibiotic Incentives Now (GAIN), orphan exclusivities and impacts on ANDAs ... Kristiana Brugger, Aaron Friedman, Katherine Schumann, Jonathan Hughes, Mindy Ehrenfried respond to audience questions. Truong Quach, Nisha Shah Alicia Chen and Christopher Pruitt discuss audience questions. Learn more at ...
Alicia Chen from the Office of Generic Drugs discusses how to submit and make changes to patent information, patent delistings, ... Elizabeth Friedman from the Office of Generic Drugs discusses the basics of therapeutic equivalence and how FDA determines if ... Kun Shen from CDER's Office of Generic Drug Policy provides a history and overview of the FDA's Kun Shen, Alicia Chen and Janice Weiner discuss audience questions. Learn more at ... CAPT Kendra Stewart from the Office of Generic Drugs discusses the recent Federal Register notices soliciting feedback on the ... Dear Viewers, In this video I have demonstrated how to search an
In this FDA Drug Topics webinar, Dr. Thanh Nguyen-Chu welcomes Dr Eva Chan. Dr Chan discusses various facts regarding the ... Camille Smith from the Office of Generic Drugs covers the "nuts and bolts" content of the Kendra Stewart, Kun Shen, Eunice Chung-Davies and Elizabeth Friedman respond to audience questions. Learn more at ...
